Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados 56 (2) Autor Chaoubah,A. (2) Bastos,M.G. (1) Beitler,B. (1) Chamone,D.A.F. (1) Dulley,F.L. (1) Hallack Neto,A.E. (1) Llacer,P.D. (1) Macedo,M.C.M.A. (1) Magacho,E.J.C. (1) Pereira,J. (1) Ribeiro,L.C. (1) Mais... Palavra-chave CHOP lymphoma treatment (1) Chronic kidney disease (1) Diffuse large B-cell lymphoma (1) Drug adherence (1) Drug therapy (1) Nursing (1) ProMACE-CytaBOM treatment (1) Self-report (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2011 (1) 2006 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Adherence to drug therapy in kidney disease 56 Magacho,E.J.C.; Ribeiro,L.C.; Chaoubah,A.; Bastos,M.G.. Non-adherence to drug therapy has not been extensively studied in patients with chronic kidney disease (CKD). The objective of the present study was to identify determinants of non-adherence to drug therapy in patients with CKD, not on dialysis. A prospective cohort study involving 149 patients was conducted over a period of 12 months. Adherence to drug therapy was evaluated by the self-report method at baseline and at 12 months. Patients who knew the type of drug(s) and the respective number of prescribed pills in use at the visit preceding the interview were considered to be adherent. Patients with cognitive decline were assessed by interviewing their caregivers. Mean patient age was 51 ± 16.7 years. Male patients predominated (60.4%). Univariate... Tipo: Info:eu-repo/semantics/article Palavras-chave: Drug adherence; Chronic kidney disease; Drug therapy; Self-report; Nursing. Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000300014 Results of CHOP chemotherapy for diffuse large B-cell lymphoma 56 Hallack Neto,A.E.; Pereira,J.; Beitler,B.; Chamone,D.A.F.; Llacer,P.D.; Dulley,F.L.; Macedo,M.C.M.A.; Chaoubah,A.. Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were determined. Primary refractory patients and relapsed patients were also assessed. A total of 111 patients under 60 years of age were assessed and ranked according to the international prognostic index adjusted to age. Twenty (18%) of them were classified as low risk, 40 (36%) as intermediate risk, 33 (29.7%) as high intermediate risk, and 18 (16.3%) as high risk. Over a five-year period, OS and DFS rates were 71 and 59%, respectively, for all patients. For the... Tipo: Info:eu-repo/semantics/article Palavras-chave: Diffuse large B-cell lymphoma; CHOP lymphoma treatment; ProMACE-CytaBOM treatment. Ano: 2006 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000007 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco